A research team from Massachusetts General Hospital describes finding a mixture of HER2-positive and HER2-negative circulating tumors cells in blood samples from patients who developed metastatic disease after originally being diagnosed with estrogen-receptor-positive/HER2-negative breast cancer.
MedicalXpress